Briefing
Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer.
The PROPHET assay, which sequences 50 patient-specific variants, was compared with fixed-panel assays in 760 plasma samples from 181 people with early-stage non-small cell lung cancer.
- Design: Evidence level 2
- Assay: PROPHET